ReviewOrthopadie (Heidelberg, Germany)2025
[Osteo-anabolic treatment strategies].
Review in Orthopadie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of Functional Performance, Bone Mineral Density, and Back Pain Under Specific Pharmacological Osteoporosis Therapy in an Elderly, Multimorbid Cohort.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Teriparatide and abaloparatide are osteoanabolic agents that promote the formation of new bone by activating the PTH1 receptor, significantly reducing the risk of fractures, particularly vertebral fractures. Romosozumab works by inhibiting sclerostin. To maintain the therapeutic benefit after osteoanabolic therapy, subsequent anti-resorptive therapy is obligatory for all of these agents. Teriparatide is approved for use in men and postmenopausal women at high risk of fracture, as well as for the treatment of glucocorticoid-induced osteoporosis. However, the approval of romosozumab and abaloparatide is currently limited to the treatment of postmenopausal women. The choice of drug should be made on a patient-specific basis, taking into account risk factors, fracture history, and comorbidities. Osteoanabolic drugs are an effective therapeutic strategy for reducing individual fracture risk and treating osteoporosis.
Indexed as
Identifiers
41114847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.